
Interventional Cardiologist ~TAVI , structural heart disease, coronary interventions @svphs @notredameaus . Running. Surfing.
Sydney, Australia
Joined May 2011
- Tweets764
- Following1.4K
- Followers2.1K
- Likes626
Dr Andrew K Roy retweeted
I built an interactive echocardiography tutorial with Claude Code.
Chapter 07: a 3D heart, the standard imaging views, the probe position, and simulated ultrasound video.
Dr Andrew K Roy retweeted
🫀 TTE cheatsheet update, now at ventriculus.org, still free.
• Updated based on feedbacks
• Drop a screenshot of measurements→ values auto-filled, cross-checked & interpreted
Runs in your browser, nothing uploaded/downloaded @ASE360
#EchoFirst #CardioTwitter
Dear cardiology fellows 🫀
I built a free TTE cheatsheet with @claudeai I keep open while reading echos: guideline cutoffs, 17-segment walls by view, valve grading and 15 built-in calculators (AVA, SV/CO).
Check it out 👇
echoguide.netlify.app
#EchoFirst #CardioTwitter
Dr Andrew K Roy retweeted
An incredible number of trials published simultaneously in the NEJM: I honestly can’t quite wrap my head around what is happening. Congratulations to everyone involved. It was difficult to choose only five trials, but these are the ones I selected for the interventional cardiology highlights. #ESCCongress
Great overview on GLP-1 drugs and weight loss pharmacotherapy current perspectives. Well worth a read.
Dr Andrew K Roy retweeted
A triple-agonist just posted 30% weight loss at two years. Surgical-magnitude, from a once-weekly shot.
And I'm convinced it's the least important thing that happened to obesity medicine this year. Here's why the biggest number stopped being the story. 🧵
Dr Andrew K Roy retweeted
I'm a cardiologist. If you've ever been told "your calcium score is zero — you're fine," I need you to read this carefully.
A new study just changed how I think about the most popular heart scan in preventive cardiology.
The NATURE-CT study — published in the Journal of Cardiovascular Computed Tomography in 2026 — tracked 205 low-risk, untreated adults with two detailed coronary CT angiograms roughly five years apart. No diabetes. No statins. No prior heart attacks. Average LDL around 112 mg/dL — what most labs still call "normal." Over half had a calcium score of exactly zero at baseline.
What happened over five years with no treatment:
Total plaque volume roughly doubled. From about 30 cubic millimeters to 59.
And here's the finding that should change how every patient and every physician thinks about the calcium score:
Nearly all the growth was non-calcified soft plaque — the lipid-rich, inflamed kind most linked to heart attacks. Soft plaque grew from 27.5 to 53.5 cubic millimeters. Calcified plaque barely moved — from 0.3 to 3.2.
The most dangerous subtype — low-attenuation plaque, the very soft, rupture-prone lesions that cause sudden cardiac events — was present in 9% of patients at baseline. Five years later: 23%. More than doubled.
Even among patients with a true zero calcium score at baseline, non-calcified plaque was often already present and grew substantially. Silently. Without symptoms.
Let me explain why this matters so much — because I've been ordering calcium scores for twenty years and I need you to understand what they can and cannot tell you.
A calcium score measures calcified plaque. Calcium in your arteries is essentially scar tissue — the healed residue of old inflammation. Think of it as a smoke detector that only detects fires that already burned out.
A zero score means: no old scarring detected. It predicts very low short-term event risk — typically a "warranty period" of 5-15 years depending on your other risk factors. That's genuinely reassuring and I still order this test regularly.
But a zero score does NOT mean zero plaque.
It means the scan is blind to the plaque that's most likely to kill you — the soft, active, lipid-rich plaque that's growing right now inside your artery walls. The plaque that ruptures without warning and causes the heart attack nobody saw coming.
This is why I've had patients on my cath lab table who said: "But my calcium score was zero two years ago."
It was zero. And the soft plaque that was already there — invisible to the calcium scan — kept growing until it ruptured.
A coronary CT angiogram with AI-enhanced plaque composition analysis is the difference between seeing old scars and seeing the active fire. It visualizes your arteries in 3D with contrast, quantifies total plaque burden, and — critically — tells me how much is soft and dangerous versus calcified and stable.
The NATURE-CT study used exactly this technology — Cleerly's AI plaque analysis — and it revealed what the calcium score alone would have completely missed: a near-doubling of dangerous plaque in "healthy" people with "normal" cholesterol over just five years.
Here's what this means for you:
If your calcium score is zero — celebrate it. It's genuinely good news. You have time. Use that time wisely.
Do not interpret it as "I'm fine forever." Plaque is building. In most adults over 40, it's already there — just in a form the calcium scan can't see.
Know your ApoB. This counts every atherogenic particle penetrating your artery walls. LDL of 112 — the average in this study — looks "normal" on a standard panel. But those particles were building plaque year after year in every single patient tracked. ApoB tells you the real particle burden. Most people have never had it checked.
Know your Lp(a). Test it once in your lifetime. 1 in 5 Americans are elevated. Completely genetic. Triples risk independently. Diet and exercise cannot lower it.
If you have risk factors — family history, elevated ApoB or Lp(a), metabolic syndrome, autoimmune disease — push for a full coronary CT angiogram with plaque analysis, not just a calcium score. The difference is the difference between seeing the scars and seeing the disease.
If soft plaque is found early, we can stabilize it. Statins don't just lower LDL — they stabilize plaque, making soft lesions harder and less likely to rupture. PCSK9 inhibitors drive LDL even lower. Lifestyle — Mediterranean diet, resistance training, sleep, stress management — reduces the inflammation that makes plaque vulnerable.
The goal of prevention isn't perfection. It's slowing the slope so dramatically that you never have an event. And the NATURE-CT data proves that the slope is steeper than we thought — even in people who look "low-risk" by every standard measure.
I've written on this platform about inflammation as the fire behind heart disease. About AI detecting inflamed arteries years before symptoms. About advanced lipid testing that catches what standard panels miss. This study ties all of it together into one devastating conclusion:
The standard playbook — check calcium score, if zero you're fine, see you in five years — is not enough.
It was never enough.
We were looking for old fires and missing the ones still burning.
Zero calcium buys you time. It buys you peace of mind. But what you do with that time — the ApoB you check, the lifestyle you build, the advanced imaging you pursue when risk factors warrant it — is what determines whether you stay healthy or become one of the patients on my table who says "but my score was zero."
Prevention works best before the calcium rises. Before the symptoms appear. Before the event that didn't have to happen.
Measure what matters. Act early. Stay ahead.
Your arteries will thank you for decades.
For decades we’ve measured cardiovascular risk.
We’re now moving toward measuring cardiovascular disease itself.
NATURE-CT provides some of the first contemporary data describing how coronary plaque progresses in untreated lower-risk adults using serial AI-CCTA, in this case #CleerlyHealth.
The most important finding isn’t plaque growth.
It’s that we can now begin to define what “normal” and “rapid” plaque progression look like.
Future preventive cardiology may track:
• ApoB
• Lp(a)
• CAC
• AI-derived plaque burden
• Plaque progression rate
The disease is becoming measurable long before the heart attack. This is great work by Dr Karlsberg and their team.
#Cardiology #Prevention #HeartHealth #Corveo
Dr Andrew K Roy retweeted
What tremendous work led by @JGrapsa making this paper a reality.
So proud of her and all our coauthors for leading the charge in. Making #womensheartcenters grow across the EU and beyond.
Our ESC Clinical Consensus Statement on Women’s Heart Centres is published in @EurHeartJ merging 4 associations @EACVIPresident @EAPCIPresident @HFA_President @ACVCPresident
Link ➡️ academic.oup.com/eurheartj/a…
ESC press release ➡️ escardio.org/news/press/pres…
This is the first statement to define what a Women’s Heart Centre actually is: its structure, its team, its referral pathways, and the training standards clinicians need to lead one.
The problem: CVD is the #1 killer of women. Yet women face systematic delays in diagnosis and treatment and the conditions most likely to affect them (INOCA, MINOCA, pregnancy-related CVD) remain underdiagnosed everywhere.
Our solution: hub-and-spoke Women’s Heart Centres, embedded in existing CV systems, not parallel structures. Advanced diagnostics, multidisciplinary care, research coordination.
For the first time we define:
✅ The nucleus clinical team
✅ Adjunct specialties (cardio-obstetrics, oncology, rheumatology, psychology and more)
✅ Core vs advanced competencies
✅ A pathway toward subspecialty certification
We also set milestones for national and institutional adoption.
This has been a Herculean effort and an important task to lead this document with enormous gratitude to senior author @DrMarthaGulati for her mentorship and friendship - really grateful to @Drroxmehran @rafavidalperez @mmamas1973 @HeartDocSharon @Bharatishivalka @PrSusannaPrice1 @Cosyns @VictoriaDe32503 @d_trabattoni @Marta33717088 @ARakisheva @yappelman @mirvatalasnag @lesleejshaw @alessia_gimelli
#WomensHealth
#Cardiology
#WomensHeartDisease
#CardioTwitter
#ESC
#EACVI
#HeartDisease
#WomensHeartCentre
#CVD
#CardioEd
Dr Andrew K Roy retweeted
Mayo Clinic and Bayesian Health just announced a partnership to commercialize an AI palliative care screening tool. The underlying randomized trial is worth understanding on its own.
The intervention was narrow. An AI/ML algorithm scored hospitalized patients for palliative care need. A control-tower operator screened the list daily. Palliative care specialists reviewed flagged patients and approached the primary team when a consult was warranted. Human in the loop at every step. The algorithm made no clinical decisions.
The design was rigorous. A pragmatic, cluster-randomized, stepped-wedge trial across 12 nursing units at two Mayo hospitals. 3,183 hospitalizations. Published in the Journal of Pain and Symptom Management (Wilson et al., 2023).
The primary outcome held. Patients in the intervention arm had a 44% higher rate of palliative care consultation (IRR 1.44, 95% CI 1.11 to 1.92).
The exploratory signal is the interesting part. 60-day readmissions were lower in the intervention group (24.5% vs 34.3%; OR 0.75). 90-day readmissions were lower as well (28.5% vs 38.7%; OR 0.72). The authors are careful to label these as exploratory and nonprespecified. They are hypothesis-generating, not confirmatory. 30-day readmission did not reach significance.
Here is why this matters beyond palliative care.
This is the category of AI that critics single out as the weak link: a risk flag inside the EHR. The Nature Medicine editorial framed exactly this kind of tool as telling you who is at risk without telling you what to do.
This trial shows what happens when you close the loop. The flag triggered a human review. The review triggered a workflow. The trial measured downstream consultation rates rather than model accuracy. The primary outcome moved.
Now consider the surface. Sepsis recognition. Medication reconciliation. Discharge planning. Specialist routing. Goals-of-care timing. Each is a touchpoint where the same pattern can apply: identify the right patient, route to the right intervention, measure the outcome.
AI will affect these unevenly. Some will move dramatically. Others will resist. But the mechanism is now demonstrated in a randomized trial with a closed-loop workflow and a primary endpoint that held.
This is what moving from prediction to deployment looks like.
Eli Lilly just released Phase 3 data for retatrutide, their next-generation obesity drug. 2,339 patients. 80 weeks. The biggest trial in the field.
8 things worth knowing:
1️⃣ It beats every obesity drug on the market. Wegovy (semaglutide): 15% Zepbound (tirzepatide): 22% Retatrutide: 25%
2️⃣ You don’t need the highest dose. The lowest (4mg) already outperforms Wegovy. 18% weight loss with one dose increase. Fewer people quit than on the sugar pill.
3️⃣ At two years, weight was still dropping. No plateau. Patients with BMI over 35 lost 84 pounds. 30% of their body weight.
4️⃣ Some patients stopped taking it because they lost too much weight. That’s never happened with an obesity drug.
5️⃣ It works differently. Ozempic and Zepbound suppress appetite. Retatrutide does that too, but its third receptor (glucagon) flips your metabolism toward burning stored fat. In Phase 2, ketone bodies rose 2-3x, confirming the body was switching fuel sources.
6️⃣ It causes a side effect no other obesity drug does: tingling and numbness (12.5%). New receptor, new trade-off. Worth watching.
7️⃣ In a separate study, it cleared 86% of liver fat. 93% of patients reached normal levels. 1 in 3 adults have fatty liver disease. No approved drug comes close.
8️⃣ Two-thirds of patients on the highest dose were reclassified out of obesity entirely. They started at BMI 40. They finished under 30. That’s not just weight loss. That’s a medical reclassification.
@US_FDA filing expected late 2026.
Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss.
gift link nytimes.com/2026/05/21/scien…
Dr Andrew K Roy retweeted
Today in @Nature, we report MouseMapper: foundation-model AI to map disease perturbations across the entire mouse body cell-by-cell.
In obesity, it revealed body-wide inflammation & unexpected facial nerve damage. 🧵👇🔉
nature.com/articles/s41586-0… led by @Dorie00 & @yingchen733
At #EuroPCR2026 in Paris, what stands out isn’t just incremental iteration — it’s the convergence of structural heart, imaging, robotics, AI-guided navigation, and device engineering into truly integrated procedural ecosystems.
From next-generation TAVR leaflet design and anchoring systems…
to ultra-flexible peripheral scaffolds…
to intravascular imaging that is becoming increasingly intelligent and actionable in real time…
The pace of innovation in interventional medicine is accelerating dramatically.
The future cath lab will be:
• more image-guided
• more data-driven
• less invasive
• more personalized
• and increasingly physiology-led rather than anatomy-led.
Exciting times to be in interventional cardiology.
#CardioTwitter #InterventionalCardiology #TAVR #PCI #MedTech #HealthTech #EuroPCR #StructuralHeart #Innovation
🤖 Made with AI
Great to be back in Paris for an exciting EuroPCR program 2026! #europcr
Dr Andrew K Roy retweeted
Can artificial intelligence detect coronary plaque progression before it becomes clinically evident? This is the first deep-learning model designed to detect changes in plaque progression by quantifying frame-to-frame changes in plaque burden across adjacent IVUS images. eurointervention.pcronline.c…
Dr Andrew K Roy retweeted
#Perspective The 2026 ACC/AHA lipid guideline adds precision, and complexity, to ASCVD prevention using risk tools, biomarkers, and imaging @GCFMD @kewatson ahajrnls.org/4f3qJc0
Dr Andrew K Roy retweeted
Our best shot for preventing many diseases?
Exercise
A @Cell_Metabolism new review
cell.com/cell-metabolism/ful…
Dr Andrew K Roy retweeted
"In 2014, he was a leader of a study that found an alternative cholesterol-lowering drug could protect people from heart attacks and strokes. The study validated previous findings that lowering cholesterol prevents heart disease — settling the issue, Dr. Braunwald insisted, once and for all."
'People,' he said, 'can stop yapping.'"
nytimes.com/2026/04/25/healt…
Dr Andrew K Roy retweeted
Golf legend @jacknicklaus has bravely stepped forward to share his ATTR-CM diagnosis.
As a cardiologist who specializes in ATTR-CM, I know how often this progressive disease flies under the radar. When icons like Jack speak out, it changes everything - raising awareness, encouraging earlier testing, and giving patients hope for timely treatment.
Thank you, @jacknicklaus. Your voice matters. Let’s get the word out!
vyndamax.com/jacks-journey




























